Cover Image
市場調查報告書

腦幹神經膠質瘤:開發中產品分析

Pontine Glioma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361620
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
腦幹神經膠質瘤:開發中產品分析 Pontine Glioma - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 148 Pages
簡介

本報告提供腦幹神經膠質瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦幹神經膠質瘤概要

治療藥的開發

  • 開發中產品的概要

腦幹神經膠質瘤:企業開發中的治療藥

腦幹神經膠質瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腦幹神經膠質瘤:企業開發中的產品

腦幹神經膠質瘤的治療藥開發企業

  • Arog Pharmaceuticals, Inc.
  • Burzynski Research Institute, Inc.
  • Loxo Oncology, Inc.
  • Medicenna Therapeutics, Inc.
  • Medivation, Inc.
  • Novogen Limited
  • Sanofi

腦幹神經膠質瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腦幹神經膠質瘤:最近的開發平台趨勢

腦幹神經膠質瘤:暫停中的計劃

腦幹神經膠質瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9389IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pontine Glioma - Overview
    • Pontine Glioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pontine Glioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pontine Glioma - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Arog Pharmaceuticals Inc
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Burzynski Research Institute Inc
    • Insys Therapeutics Inc
    • Loxo Oncology Inc
    • Medicenna Therapeutics Corp
    • Midatech Pharma Plc
    • Novogen Ltd
    • Ono Pharmaceutical Co Ltd
    • Pfizer Inc
    • Sanofi
    • ZIOPHARM Oncology Inc
  • Pontine Glioma - Drug Profiles
    • (A-10 + AS-21) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AdRTSIL-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-1775 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • depatuxizumab mafodotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab + nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • larotrectinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDNA-55 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTX-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • R&D Progress
    • ORX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pidilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Trilexium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Pontine Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIMO-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pontine Glioma - Dormant Projects
  • Pontine Glioma - Product Development Milestones
    • Featured News & Press Releases
      • Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
      • Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
      • Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier
      • May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pontine Glioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pontine Glioma - Pipeline by AbbVie Inc, H1 2017
  • Pontine Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017
  • Pontine Glioma - Pipeline by AstraZeneca Plc, H1 2017
  • Pontine Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Pontine Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H1 2017
  • Pontine Glioma - Pipeline by Insys Therapeutics Inc, H1 2017
  • Pontine Glioma - Pipeline by Loxo Oncology Inc, H1 2017
  • Pontine Glioma - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Pontine Glioma - Pipeline by Midatech Pharma Plc, H1 2017
  • Pontine Glioma - Pipeline by Novogen Ltd, H1 2017
  • Pontine Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Pontine Glioma - Pipeline by Pfizer Inc, H1 2017
  • Pontine Glioma - Pipeline by Sanofi, H1 2017
  • Pontine Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Pontine Glioma - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Pontine Glioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top